Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases

Junfa Yang1,2,3, Changyao Li1,2,3, Lei Zhang1,2,3* and Xiao Wang4*

1 School of Pharmacy, Anhui Medical University, Hefei, China, 2 Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Hefei, China, 3 The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Anhui Medical University, Hefei, China, 4 Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Extracellular vesicles (EVs) are small membranous vesicles secreted from normal, diseased, and transformed cells in vitro and in vivo. EVs have been found to play a critical role in cell-to-cell communication by transferring non-coding RNAs (ncRNAs) including microRNAs (miRNAs), long ncRNAs (lncRNAs) and so on. Emerging evidence shows that transferring biological information through EVs to neighboring cells in intercellular communication not only keep physiological functions, but also participate in the pathogenesis of liver diseases. Liver diseases often promote release of EVs and/or in different cargo sorting into these EVs. Either of these modifications can promote disease pathogenesis. Given this fact, EV-associated ncRNAs, such as miR-192, miR-122 and lncRNA-ROR and so on, can serve as new diagnostic biomarkers and new therapeutic targets for liver disease, because altered EV-associated ncRNAs may reflect the underlying liver disease condition. In this review, we focus on understanding the emerging role of EV-associated ncRNAs in viral hepatitis, liver fibrosis, alcoholic hepatitis (AH), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) and discuss their utility in biomarker discovery and therapeutics. A better understanding of this multifaceted pattern of communication between different type cells in liver may contribute to developing novel approaches for personalized diagnostics and therapeutics.

Keywords: non-coding RNAs, mRNAs, EVs, liver disease, DNA

INTRODUCTION

Understanding the intercellular communication is rapidly becoming the new frontier in multicellular organisms. It is now widely accepted that cell-to-cell communicate not only by direct contact or soluble factors but also through released cell membrane fragments known as extracellular vesicles (EVs) (Howlett and Bissell, 1993; Lee et al., 2011). EVs are membrane-bound vesicles that are released by normal and transformed cells into their environment. Although EVs were first identified in the late 1970s, it has only recently served as the points of focus in the scientific community (Penfornis et al., 2016). Increasing evidence have showed that EVs can be released by most cell types and detected all major bodily fluids, including blood, urine, bile, saliva, breast milk, as well as in cirrhosis associated ascites (Bobrie et al., 2011; Colombo et al., 2014; Yanez-Mo et al., 2015). Emerging studies have also identified that EVs can serve as a unique vehicle for the release of soluble and insoluble molecules and was associated with several physiological and pathophysiological processes, such as inflammation, immune modulation, neurological diseases,
As is well-known, ncRNAs are usually divided into two main classes according to their size: (1) short ncRNAs (<200 nt), such as miRNAs, endogenous small interfering RNA (siRNA) and piwi-interacting RNA (piRNA); (2) long ncRNAs (lncRNA; >200 nt) (Mercer et al., 2009; Prensner and Chinnaiyan, 2011; Raposo and Stoorvogel, 2013). Although ncRNAs are unable to encode protein, they have specific biological function of regulating the levels of proteins and miRNAs of target genes, interacting with proteins to disturb their function, and interacting one with each other to finely tune their expression (Ling et al., 2013) (Table 2).

The miRNAs, such as miR-145 and miR-122, are the most broadly reported ncRNA in the literature, since the first small ncRNA lin-4, in C. elegans, was described in 1993 (Lee et al., 1993; Wightman et al., 1993). miRNAs are a broad class of endogenous short ncRNAs that are approximately ~22 nucleotides in length and can regulate gene expression by silencing or post-transcriptionally (Ambros, 2004; Bartel, 2004; Malizia and Wang, 2011; Yates et al., 2013). Of note, miRNAs were reported to target many genes and involved in regulation cell proliferation and differentiation, migration, apoptosis, and modulation of the host response to viral infection (Bartel, 2004; Salmanidis et al., 2014). Alterations in miRNAs expression profiles have been shown to be associated viral hepatitis, hepatobiliary malignancies, non-alcoholic fatty liver disease, acute liver injury from acetaminophen and liver fibrosis (Jiang et al., 2010; Cermelli et al., 2011; Starckx et al., 2013; Szabo and Bala, 2013; Yao et al., 2017). Interestingly, miRNAs not only exert their function intracellularly, but also can be exported from cells in the extracellular space via EVs or bound to proteins (Vickers et al., 2011; Boon and Vickers, 2013). Furthermore, increasing evidence suggests that EVs can protect miRNAs from the degradation of RNases, thus elevate the stability of miRNAs (Boon and Vickers, 2013). It is therefore not surprising that miRNAs have been considered as a novel class of biomarkers in liver diseases (Ghi and Braconi, 2015). Noteworthy, the function of miR-181b in serum from 22 patients with liver cirrhosis was elevated. In turn, miR-181b promoted HSC-T6 proliferation by targeting the cell cycle regulator p27 (Wang et al., 2012). A panel of seven plasma miRNAs (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801) was shown to have a high-diagnostic accuracy of HCC (Ghidini and Braconi, 2015). Furthermore, recent studies have revealed that the levels of miRNA-122 were remarkably increased and almost exclusively detected in circulating EVs but not in the non-EV fractions in HCC (El-Abd et al., 2015).

Long ncRNAs are the most heterogeneous class of non-protein-coding RNAs with length from 200 nt to 100 kb. Although, the lncRNAs are expressed at low levels compared with miRNAs, they have been shown to exhibit tissue or cell type-specific expression (Ghidini and Braconi, 2015). Similarly to miRNAs, most lncRNAs have many features in common with miRNAs, as transcription by RNA polymerase II, polyadenylation and splicing mechanisms (Guttman et al., 2009; Binder et al., 2011). With the rapid growth of lncRNA study, the landscape of IncRNAs has been unveilled by the rapid development of deep sequencing technology along with the development of bioinformatics tools (He et al., 2014a). According to their genomic proximity to protein-coding genes, IncRNAs have been divided into four categories: sense IncRNAs, antisense IncRNAs, bidirectional or divergent IncRNAs and intergenic IncRNAs (Tang et al., 2013; Rodriguez-Malave and Rao, 2016). Due to IncRNA complex structure features, it is also offers multiple possibilities for interactions with DNA, RNA, and/or protein (Van Roosbroeck et al., 2013). Noteworthy, the function of lncRNAs was associated with their cellular localization (Zhang et al., 2014). In the nucleus, some lncRNAs can influence chromatin architecture through interacting with chromatin-modulating proteins which can facilitate their recruitment and/or combine to chromatin, thereby regulating transcriptional activity (Gonzalez et al., 2015; Scarola et al., 2015; Liu et al., 2017; Wang and Dostie, 2017). In the cytoplasm, lncRNAs seem to bind to the ribosome. Emerging studies have also identified that lncRNAs can act as molecular decoys for proteins or miRNAs (Carlevaro et al., 2016). Likewise, lncRNAs, act like...
miRNA sponges, modulate the microRNome by binding one or multiple miRNAs (Giroud and Scheideler, 2017). To our knowledge, lncRNAs has been shown to play major roles and biomarkers in disease genesis and diagnosis. Growing evidence is now suggesting that the lncRNAs was associated with pathophysiological conditions, including cancer, diabetes, liver disease and some other complex disorders (Reddy et al., 2014; Carnero et al., 2014). Dysregulated lncRNA-MALAT1 expression is associated with inflammation and fibrosis in NASH disease and some other complex disorders (Reddy et al., 2014; Gooding et al., 2017; Shan et al., 2017). For example, ISR2, ISR8, linc-ISG15, and BISPR are upregulated in HCV-infected livers and cultured cells through the IFN signaling pathway (Barriocanal et al., 2016; Shan et al., 2017). These lncRNAs might contribute to oncogenesis during the development of HCC. For example, linc-RoR can regulate the development of HCC. These lncRNAs might contribute to oncogenesis during the development of HCC. For example, linc-RoR can regulate cell viability of HCC cells during hypoxia (Takahashi et al., 2014a).

To conclude, ncRNAs can be released into the extracellular medium associated with lipoproteins or encapsulated in EVs, thus participating in cell-to-cell communication (Bobrie et al., 2011). These findings add attention to explore the functions of ncRNAs, especially EV-associated ncRNAs, because they imply that the message delivered by each EV-associated ncRNAs may be amplified according to the expression of their isoforms.

### EV-Associated Non-coding RNAs

The word “EV” is actually a collective term that refers to a series of lipid bilayer membrane-bound organelles that are released by cells into their environment (Figure 1). In the last years, the discovery of EVs has represented a revolution and a paradigm shift (Figure 2A). EVs are heterogeneous in size and are released from nearly all cells under both physiological and pathological conditions (Lee et al., 2011). Currently, more specific nomenclature for EVs bases on their size, biogenesis, and secretion mechanisms including exosomes, ectosomes, microvesicles, apoptotic bodies and oncosomes (Yanez-Mo et al., 2015). Nevertheless, exosomes and microvesicles are the most commonly used as the term ‘EVs’. Exosomes (40–100 nm diameter) are originated from the inward and reverse budding of an endosomal membrane and are released into the extracellular space following fusion of multivesicular bodies (MVBs) with the plasma membrane (Colombo et al., 2014; Robbins and Morelli, 2014). Microvesicles (100–1,000 nm diameter), larger than exosomes, are cell surface-derived EVs that directly bud from the plasma membrane (Camussi et al., 2011).

In 2007, EVs was first supposed to be an important mediator of many biological events through transferring genetic information to target cells (Valadi et al., 2007). Nowadays, growing evidence showed that EVs play a key role in intercellular communication through delivery their cargo (proteins, RNAs, and lipids) (Ekstrom et al., 2012). The recognition that EVs released from a cell can be absorbed by another and transfer their cargo (Penfornis et al., 2016). The EV cargo partly reflects the cells of origin, and especially exosomes have been shown to carry different RNA species compared to their parental cells (Skog et al., 2008; Ekstrom et al., 2012; Nolte-’t Hoen et al., 2012). In fact, transfer of EV cargo is one of mechanisms about intercellular communication (Mathivanan et al., 2010; Ling et al., 2013). It is known that unprotected ncRNAs are easily degraded by the RNases in blood. However, EVs can protect ncRNAs from degradation and maintains their integrity and activity in the circulation. According to an exosome database, ExoCarta, 4,563 proteins, 194 lipids, 1,639 mRNAs, and 764 miRNAs have been identified in exosomes which were released from different cells (Kosaka et al., 2013; Yang et al.,

### Table 2: EV-associated ncRNAs in liver disease.

| ncRNAs    | Expression | Liver disease | Function                  | Citation                          |
|-----------|------------|---------------|---------------------------|----------------------------------|
| miR-122   | Up         | HCV           | Biomarker                 | Biher et al., 2011               |
| miR-192   | Up         | AH            | Diagnostic markers        | Ghidiri and Bracuni, 2015        |
| miR-21    | Up         | HCC           | Inhibitor apoptosis       | Goma et al., 2008                |
| miR-18a   | Up         | HCC           | Promotes cell proliferation | Sohn et al., 2015               |
| miR-221   | Up         | HCC           | Promotes growth and invasion of cells | Sohn et al., 2015 |
| miR-222   | Up         | HCC           | Promoters proliferation   | Sohn et al., 2015               |
| linc-VLDLR| Up         | HCC           | Promotes chemoresistance  | Groud and Scheideler, 2017       |
| linc-RoR  | Up         | HCC           | Promotes tumor            | Loewer et al., 2010; Nath and Szabo, 2012 |
| miR-718   | Down       | HCC           | Inhibitor proliferation   | Sugimachi et al., 2017           |
| miR-199a  | Down       | HCV           | Inhibitor of HCV transmission | El Abd et al., 2015 |
| miR-30a   | Up         | AH            | Potential diagnostic markers | Momen-Heravi et al., 2015        |
| miR-122   | Up         | NASH          | Biomarker                 | Miyake et al., 2014              |
| miR-182   | Up         | AH            | Increases inflammatory mediators | Bliya et al., 2016 |
| miR-193b  | Down in HCC, up in HCV-HCC | HCC HBV-HCC | Diagnostic tool/biomarker | Braconi et al., 2010; Mao et al., 2014 |
EVs under \textit{in vitro} conditions, many types of cells in the liver have the capacity to secrete EVs and their contents (Xie et al., 2013). Growing research has suggested that some non-coding RNAs in EVs are selectively enriched and specific to cell of origin. MHC, major histocompatibility complex.

FIGURE 1 | Extracellular vesicles (EVs). EVs contain several types of molecules, proteins, DNA, miRNA, lncRNA, and mRNA, some of which are selectively enriched and specific to cell of origin. MHC, major histocompatibility complex.

Liver Fibrosis
Liver fibrosis is characterized by extensive deposition of extracellular matrix (ECM) and an activation of HSCs resulting from a protracted wound-healing response (Schuppan and Brenner, 2006, 2007). Following liver fibrosis of any cause, HSCs were activated, which is the transition of quiescent HSCs into proliferative, fibrogenic, and contractile myofibroblasts (Schuppan and Kim, 2013). Of note, it has been recognized that suppression of the activation of HSCs can prevent and treat liver fibrosis (Lee and Friedman, 2011). Some studies have reported that pathological HSCs migration can be regulated by endothelial cell-derived EVs during liver fibrosis (Wang et al., 2015). The study found that EVs induced HSCs migration through EVs adhesion. Additionally, many studies found that EV-associated ncRNAs could also regulate the activation and proliferation of HSCs through regulating anti- and pro-fibrotic gene expression (Royo and Falcon-Perez, 2012; Matsuura et al., 2016). In a recent study, connective tissue growth factor (CTGF) promotes fibrogenesis in HSCs. miR-214 can specifically target the 3′-UTR regions of CTGF in activated HSCs. Interestingly, miR-214 in EVs derived from HSCs suppressed CTGF 3′-UTR region activity and thus inhibit the expression of CTGF. Nonetheless, the same group demonstrated afterward that CTGF is also loaded into EVs and transferred between HSCs, resulting in an increase in the level of alpha smooth muscle in the recipient HSCs (Charrier et al., 2014; Chen et al., 2014; Lee and Friedman, 2011). Some studies have reported that pathological HSCs migration can be regulated by endothelial cell-derived EVs during liver fibrosis (Wang et al., 2015). The study found that EVs induced HSCs migration through EVs adhesion. Additionally, many studies found that EV-associated ncRNAs could also regulate the activation and proliferation of HSCs through regulating anti- and pro-fibrotic gene expression (Royo and Falcon-Perez, 2012; Matsuura et al., 2016). In a recent study, connective tissue growth factor (CTGF) promotes fibrogenesis in HSCs. miR-214 can specifically target the 3′-UTR regions of CTGF in activated HSCs. Interestingly, miR-214 in EVs derived from HSCs suppressed CTGF 3′-UTR region activity and thus inhibit the expression of CTGF. Nonetheless, the same group demonstrated afterward that CTGF is also loaded into EVs and transferred between HSCs, resulting in an increase in the level of alpha smooth muscle in the recipient HSCs (Charrier et al., 2014; Chen et al., 2014; Lee et al., 2017). Additionally, studies found that EVs derived from hepatocyte regulate HSCs via miR-128-3p targeting PPAR-γ. miRNAs in Hepatocyte-derived EVs are known inhibitors of PPAR-γ expression with miR-128-3p being the most effectively transferred. Furthermore loss- and gain-of-function studies
identified miR-128-3p as a central modulator of the effects of EVs on PPAR-γ inhibition and HSC activation (Povero et al., 2015). Furthermore, pathway analysis suggested that low levels of let-7 in EVs may influence hepatic fibrogenesis through activation of transforming growth factor β signaling in HSCs (Matsuura et al., 2016). Hence, ncRNAs derived from EVs serve as fibrosis regulators and may be considered as biomarkers of liver fibrosis.

In addition, studies found that EVs derived from platelets or granulocytes in patients with sepsis have function of promote coagulation and suggested thrombin generation, in proportion to the severity of the disseminated intravascular coagulopathy (Nieuwland et al., 2000; Owens and Mackman, 2011). However, many kinds of studies have demonstrated that coagulation activation enhances liver fibrosis (Valla, 2008; Dhar et al., 2017). Therefore, EVs might also promote fibrogenesis. Thence, ncRNAs in EVs may act as a key regulator in liver fibrosis s by promoting migration and activation of HSCs, in addition to their known anti-fibrosis function.

**Alcoholic Hepatitis**

Alcoholic hepatitis (AH) is an acute hepatic inflammation accompanied with intrinsical morbidity and mortality and increasing health problems across the world. AH is a result of the complex interactions between ethanol metabolism, inflammation, and innate immunity on the liver (Orman et al., 2013). Currently the most commonly used indicators in liver damage are the enzymatic activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in blood. However, serum elevated ALT and AST are poor specificity for liver disease (Kim et al., 2008). Several recent studies have focused on the effect of ncRNAs in EVs on AH. Recent studies showed that EVs could serve as potential diagnostic markers for AH (Momen-Heravi et al., 2015). Macrophage phenotype can be regulated by EVs derived from hepatocyte and monocyte, thereby EVs enhance inflammation in AH. Interestingly, previous studies demonstrated that several ncRNAs have been thought to be linked to EVs-associated cell-to-cell signaling, including miR-192 and miR-30a (Momen-Heravi et al., 2015).

Several reports have confirmed that the miRNAs cargo within EVs derived from sera of alcohol-fed mice are potential novel biomarkers in AH. MiR-192 and miR-30a were considered as EV cargos that were significantly increased in the circulation of subjects with AH (Momen-Heravi et al., 2015). Additionally, a growing body of evidence shows that the protein cargoes...
within EVs derived from alcohol-treated hepatocytes stimulate macrophage activation via Hsp90. For example, CD40 ligand was considered as an EV cargo that could induce the activation and infiltration of macrophages in AH (Verma et al., 2016). These findings indicate that cells in disease conditions promote the secretion of EVs containing unique molecules, and lead to diverse pathophysiological events. Importantly, studies on EV-associated ncRNAs have also been carried out human specimens that focus on the potential biomarkers of EV-associated ncRNAs in AH. Studies suggested that EVs is significantly increased in alcohol-fed mice and human subjects with AH. miRNAs of exosomes were significantly up-regulated in alcohol-fed mice compared to pair-fed mice and had valuable diagnostic values including miR-192 and miR-30a. Consistently, miRNA-30a and miRNA-192 were increased significantly in exosomes derived from plasma of AH patients (Momen-Heravi et al., 2015). Indeed, further studies are required to understand if EVs-associated ncRNAs has a biomarker value in the diagnosis and prognosis of AH.

**Non-alcoholic Steatohepatitis**

Non-alcoholic fatty liver disease (NAFLD) is a dominant cause of chronic liver disease around the world. NAFLD has become a severe health issue and can progress toward a more severe form of the disease, the non-alcoholic steatohepatitis (NASH) (Alazawi et al., 2010). NASH is characterized by lobular and portal inflammatory infiltrates of monocyte-derived macrophages, neutrophils and lymphocytes and so on. Over the last few years, cell-derived EVs have been considered as effective regulators in cell-to-cell communication that transfer several bioactive molecules in target cells, regulating the pathogenesis and progression of NASH (Povero et al., 2013). Study results demonstrated that the levels of blood EVs were increased during the progression of NASH and were strongly associated with some key outcomes of NASH in experimental models of NASH (Povero et al., 2014). The bioavailability of EVs in biofluids is only one of the fascinating aspects of these effective “messengers.” Indeed, the composition of EVs implies a special potentiality for biomarker development. As a proof of this, ncRNAs packaged in EVs have increasingly manifested great potential to meet several criteria for being considered as good biomarkers (Lai et al., 2014; Becker et al., 2015). They found that ncRNAs in EVs were significantly different in patients with NASH compared to control, such as miR-192 and miR-122. Insights into the potentiality of ncRNAs in EVs as biomarkers were provided by the observation that the expression of miRNA-122 and miRNA-192 were increased in circulating exosomes from advanced stage NAFLD patients compared to those from early stage NAFLD patients (Lee et al., 2017). The increase of miRNAs from stressed or damaged hepatocytes during NAFLD progression may be related to the decreased expression level of miR-122 found in the livers of patients with advanced NAFLD and early stage hepatocarcinogenesis from NASH, as recently reported (Esau et al., 2006; Cheung et al., 2008; Takaki et al., 2014). Therefore, this miRNA level in EVs might be useful as a biomarker for the diagnosis of advanced NAFLD or NASH. Consequently, these findings provide important support to the development of biomarkers. EV-associated ncRNAs can be used for biomarkers to make novel and non-invasive diagnostic strategies for NASH.

**Hepatocellular Carcinoma (HCC)**

Hepatocellular carcinoma (HCC) is the most common malignancy and the third leading cause of cancer-related death worldwide. HCC has been certificated to be highly refractory to treatment (Gomaa et al., 2008; Alazawi et al., 2010; Forner et al., 2018). The crosstalk of the tumor microenvironment with cancer cells is essential for tumor progression (Tlsty and Coussens, 2006). Previous studies have demonstrated that EVs play a regulatory role in cell-to-cell communication, including cancer cells. Additionally, it was also shown that tumors prepare their own tumor niches through the release of EVs (Becker et al., 2016; Wendler et al., 2017). EVs when were absorbed by HCC cells promote their migration, invasion, and proliferation. Furthermore, many studies have evaluated the role of EVs mediated ncRNAs in hepatocarcinogenesis and tumor progression (Wang et al., 2018). For instance, bona fide miRNA biomarker in serum exosomes predicts HCC recurrence after liver transplantation (LT). The studies found that miR-718 showed significantly different expression in the serum exosomes of HCC cases with recurrence after LT compared with those without recurrence (Sugimachi et al., 2015). Of note, ncRNAs were shown to have diagnostic, prognostic, and therapeutic potential in HCC. EVs mediated ncRNAs transfer between HCC cells was considered as an important regulator to local spread and multifocal growth, such as miR-584, miR-517c and miR-378 (Kogure et al., 2011). The activation of MAPK pathway could induce the epithelial mesenchymal transition and up-regulate cyclin-dependent kinase 2 (CDK2) and MMP2 expression to promote cell proliferation and metastasis. Interestingly, EVs mediated miR-320a could function as anti-tumor miRNAs by binding to its direct downstream target PBX3 to suppress HCC cell proliferation, migration and metastasis. The miR-320a-PBX3 pathway inhibited tumor progression by suppressing the activation of the MAPK pathway in HCC (Zhang et al., 2017). Hence, these observations indicate that EV-associated ncRNAs act as HCC modulators and may serve as a biomarker of HCC.

On the other hand, growing studies showed that EV-mediated lncRNAs can regulate gene expression via various mechanisms. EV-mediated transfer of lncRNA as a mechanism by which tumor cells can modulate their local cellular environment (Kogure et al., 2013; Conigliaro et al., 2015). These results demonstrated that lncRNAs can also act as biomarkers in HCC. Furthermore, HCC-derived EVs may enhance the host antitumor immune responses (Lv et al., 2012). EV-associated shuttle of lncRNAs specifically lnc-VLDLR and lnc-ROR enhance chemoresistance of malignant cells. The antitumor ability of natural killer (NK) cells can be increased heat shock proteins (HSPs)-harboring exosomes derived from HCC, thus promoting HCC immunotherapy. The study provides evidence that the expression of lnc-VLDLR was up-regulated...
by multiple anticancer agents in HCC cells and EVs derived from HCC cells (Takahashi et al., 2014b). Interestingly, chemotherapy-mediated cell death can be decreased by these EVs, along with up-regulation of Inc-VLDLR expression in the recipient cells. The knockdown of Inc-VLDLR inhibits cell viability. Therefore, Inc-VLDLR was EV-enriched a IncRNA that regulate HCC cell chemoresistance. Collectively, EV-associated ncRNAs play multiple roles in mediating progression, metastasis and thus can be used as a potential therapy for the treatment of HCC. In addition, EV-associated ncRNAs species could be exploited for the non-invasive diagnosis of HCC.

### SUMMARY AND FUTURE PROSPECTS

In conclusion, we have highlighted several of the most recent and original studies reporting the role of ncRNAs in EVs as link between liver fibrosis, viral hepatitis, NASH, AH and HCC. The association of specific EV constituents with disease offers potential for the use of EVs as biomarkers to diagnose and predict behavior or treatment response in many different types of liver diseases (Figure 3). Our knowledge about EVs has been rapidly growing in recent years, along with the analyses of protein, mRNA, ncRNAs and lipid in EVs. We search recently published articles about EV-associated ncRNAs by using PubMed tool. We found that EV-associated ncRNAs are increasingly recognized as essential regulators of biological processes in normal and pathological conditions thus having a high potential to targeted delivery and therapeutic intervention in liver and other diseases. There are evidences that ncRNAs in EVs may sear as or transfer damage-related molecular patterns to recipient cells of the liver micro-environment and coordinate many of the main pathological events occurring concurrently during the liver disease progression. Therefore, the ncRNAs in EVs may become specific biomarkers for liver disease if research will reveal that ncRNAs are indeed differ in different pathologies, and technologies will be advanced to allow the routine detection of the ncRNAs in individual samples. Nevertheless, the information that can be acquired by the detailed detection of EVs-associated ncRNAs is already contributing to understand the pathogenesis of liver diseases, and will do so even more in the future. Our previous researches showed that ncRNAs play regulatory roles in...
Wnt/β-catenin pathway. EVs are being developed also as highly multifunctional drug delivery tools with new features. Thus EVs-associated ncRNAs are one of the more promising fields of investigation in liver diseases, with the potential to shed light on pathogenic mechanisms, to reveal long needed biomarkers. It is hoped that these efforts will be soon translated into clinical practice. To achieve this goal, a combination of clinically driven, genetically defined, morphologically classified, and molecular-based study will have to be performed. Multidisciplinary research group with differential background should cooperate to successfully address these issues.

REFERENCES

Alazawi, W., Cunningham, M., Dearden, J., and Foster, G. R. (2010). Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment. Pharmacol. Ther. 32, 344–355. doi: 10.1111/j.1365-2036.2010.04370.x

Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350–355. doi: 10.1038/nature02871

Barriocanal, M., Carnero, E., Segura, V., and Fortes, P. (2014). Long non-coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor tetherin. Front. Immunol. 5:655. doi: 10.3389/fimmu.2014.00655

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297. doi: 10.1016/S0092-8674(04)00045-5

Becker, A., Thakur, B. K., Weiss, J. M., Kim, H. S., Peinado, H., and Lyden, D. (2016). Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30, 836–848. doi: 10.1016/j.ccell.2016.10.009

Becker, P. P., Rau, M., Schmitt, J., Malsch, C., Hammer, C., Bantel, H., et al. (2015). Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic Steatohepatitis. PLoS One 10:e0142661. doi: 10.1371/journal.pone.0142661

Bihrer, V., Friedrich-Rust, M., Kronenberg, B., Forestier, N., Haupenthal, J., Shi, Y., et al. (2011). Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 106, 1663–1669. doi: 10.1038/ajg.2011.161

Binder, M., Eberle, F., Seitz, S., Macke, N., Huber, C. M., Kiani, N., et al. (2011). Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-1 (RIG-I). J. Biol. Chem. 286, 27278–27287. doi: 10.1074/jbc.M111.256974

Blaya, D., Coll, M., Rodrigo-Torres, D., Vilà-Casesadesus, M., Altamirano, J., Llopis, M., et al. (2016). Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut 65, 1535–1545. doi: 10.1136/gutjnl-2015-311314

Bobrie, A., Colombo, M., Raposo, G., and Thery, C. (2011). Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659–1668. doi: 10.1111/j.1600-0854.2011.01225.x

Boon, R. A., and Vickers, K. C. (2013). Intercellular transport of microRNAs. Arterioscler. Thromb. Vasc. Biol. 33, 186–192. doi: 10.1161/ATVBAHA.112.300139

Braconi, C., Valeri, N., Gasparini, P., Huang, N., Taccioli, C., Nuovo, G., et al. (2010). Hepatitis C Virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 16, 957–966. doi: 10.1158/1078-0432.CCR-09-1923

Bukong, T. N., Momen-Heravi, F., Kody, K., Bala, S., and Szabo, G. (2014). Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-mir122-Hsp90. PLoS Pathog. 10:e1004424. doi: 10.1371/journal.ppat.1004424

Camussi, G., Deregibus, M. C., Bruno, S., Grange, C., Fonsato, V., and Tetta, C. (2011). Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 1, 98–110.

Carlevaro, C. M., Irastorza, R. M., and Vericat, F. (2016). Quaternionic representation of the genetic code. Biosystems 141, 10–19. doi: 10.1016/j.biosystems.2015.12.009

Carnero, E., Barriocanal, M., Segura, V., Guruceaga, E., Prior, C., Borner, K., et al. (2014). Type I interferon regulates the expression of long non-coding RNAs. Front. Immunol. 5:548. doi: 10.3389/fimmu.2014.00548

Cermelli, S., Ruggieri, A., Marrero, J. A., Ioannou, G. N., and Beretta, L. (2011). Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6:e23937. doi: 10.1371/journal.pone.0023937

Charrier, A., Chen, R., Chen, L., Kemper, S., Hattori, T., Takigawa, M., et al. (2014). Exosomes mediate intercellular transfer of pro-fibrogenic connective tissue growth factor (CCN2) between hepatic stellate cells, the principal fibroblastic cells in the liver. Surgery 156, 548–555. doi: 10.1016/j.surg.2014.04.014

Chen, L., Charrier, A., Zhou, Y., Chen, R., Yu, B., Agarwal, K., et al. (2014). Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 59, 1118–1129. doi: 10.1002/hep.26768

Chen, L., Chen, R., Kemper, S., Charrier, A., and Brigstock, D. R. (2015). Suppression of fibrogenic signaling in hepatic stellate cells by Twi1-dependent microRNA-214 expression: role of exosomes in horizontal transfer of Twi1. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G491–G499. doi: 10.1152/ajpgi.00140.2015

Cheung, O., Puri, P., Eicken, C., Contos, M. J., Mirshahi, F., Maher, J. W., et al. (2008). Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48, 1810–1820. doi: 10.1002/hep.22569

Colombo, M., Raposo, G., and Thery, C. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289. doi: 10.1146/annurev-cellbio-101512-122326

Conigliaro, A., Costa, V., Lo Dico, A., Saiava, L., Buccheri, S., Dieli, F., et al. (2015). CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 IncRNA. Mol. Cancer 14:155. doi: 10.1186/s12943-015-0426-x

Cossetti, C., Iraci, N., Mercer, T. R., Leonardi, T., Alpi, E., Drago, D., et al. (2014). Extracellular vesicles from neural stem cells transfer IFN-γamma via Ifnγ1 to activate Stat1 signaling in target cells. Mol. Cell 56, 193–204. doi: 10.1016/j.molcel.2014.08.020

Dhar, A., Mullish, B. R., and Thursz, M. R. (2017). Anticoagulation in chronic liver disease. J. Hepatol. 66, 1313–1326. doi: 10.1016/j.jhep.2017.01.006

do Amaral, A. E., Cisilotto, J., Creczynski-Pasa, T. B., and De Lucca Schiavon, L. (2010). Hepatitis C virus proteins modulate microRNA expression. Mol. Med. Chem. 00140.2015

El-Abd, N. E., Fawzy, N. A., El-Sheikh, S. M., and Soliman, M. E. (2015). Circulating microRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol. Diagn. Ther. 19, 213–220. doi: 10.1007/s12941-015-0148-1
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. *Cell Metab.* 3, 87–98. doi: 10.1016/j.cmet.2006.01.005

Fagone, P., Mangano, K., Pesce, A., Portale, T. R., Paleu, S., and Nicoletti, F. (2016). Emerging therapeutic targets for the treatment of hepatic fibrosis. *Drug Discov. Today* 21, 1224–1235. doi: 10.1016/j.drudis.2015.10.015

Forner, A., Reig, M., and Bruix, J. (2018). Hepatocellular carcinoma. *Lancet* 391, 1301–1314. doi: 10.1016/S0140-6736(18)30010-2

Ghidini, M., and Braconi, C. (2015). Non-coding RNAs in primary liver cancer. *Front. Med.* 2:36. doi: 10.3389/fmed.2015.00036

Ghosal, S., Das, S., and Chakrabarti, J. (2013). Long noncoding RNAs: new players in the molecular mechanism for maintenance and differentiation of pluripotent stem cells. *Stem Cells Dev.* 22, 2240–2253. doi: 10.1089/scd.2013.0014

Giroud, M., and Scheideler, M. (2017). Long Non-coding RNAs in metabolic organs and energy homeostasis. *Int. J. Mol. Sci.* 18:2578. doi: 10.3390/ijms18122578

Giugliano, S., Kriss, M., Golden-Mason, L., Dobrinskikh, E., Stone, A. E., Soto-Ghidini, M., and Braconi, C. (2015). Non-coding RNAs in primary liver cancer. *Genes Cancer* 6, 245–252. doi: 10.1089/gcan.2014.0211

Gooding, A. J., Zhang, B., Jahanbani, F. K., Gilmore, H. L., Chang, J. C., Gomaa, A. I., Khan, S. A., Toledano, M. B., Waked, I., and Taylor-Robinson, S. D. (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J. Gastroenterol.* 14, 4300–4308. doi: 10.3748/wjg.v14.i43.4300

Hoshino, A., Costa-Silva, B., Shen, T. L., Rodrigues, G., Hashimoto, A., Tesic, M., et al. (2018). Extracellular vesicles in liver diseases. *J. Gastroenterol. Hepatol.* 22(Suppl. 3), S84–S87. doi: 10.1111/jgh.14214

Kisseleva, T., and Brenner, D. A. (2007). Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. *J. Gastroenterol. Hepatol.* 22(Suppl. 1), S73–S78. doi: 10.1111/j.1440-1746.2006.04588.x

Lee, R. C., Feinbaum, R. L., and Ambros, V. (2001). The *C. elegans* heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* 75, 843–854. doi: 10.1016/0092-8674(93)90529-Y

Lee, Y. S., Kim, S. Y., Ko, E., Lee, J. H., Yi, H. S., Yoo, Y. J., et al. (2017). Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. *Sci. Rep.* 7:12698. doi: 10.1038/s41598-017-12716-6

Grazul, B. A., Malizia, A. P., and Wang, D. Z. (2011). MicroRNAs in cardiomyocyte development. *Cell Mol. Life Sci.* 68, 431–447. doi: 10.1007/s00018-010-0536-8

Hwang, S. Y., Oh, Y. J., and Lee, J. (2012). Long Non-coding RNAs: novel insights into hepatocellular carcinoma. *Front. Oncol.* 2, 154. doi: 10.3389/fonc.2012.00154

Jiang, X., Tsitsiou, E., Herrick, S. E., and Lindsay, M. A. (2010). MicroRNAs and the mammary epithelium. *FEBS J.* 277, 2015–2021. doi: 10.1111/j.1742-4658.2010.07632.x

Keerthikumar, S., Chisanga, D., Ariyaratne, D., Al Saffar, H., Anand, S., Zhao, K., et al. (2016). ExoCarta: a web-based compendium of exosomal cargo. *J. Mol. Biol.* 428, 688–692. doi: 10.1016/j.jmb.2015.09.019

Kim, W. R., Flamm, S. L., Di Bisceglie, A. M., Bodenheimer, H. C., and Public Policy Committee of the American Association for the Study of Liver, Disease. (2007). Sensitivity of alanine aminotransferase (ALT) as an indicator of health and disease. *Hepatology* 46, 1363–1370. doi: 10.1002/hep.22119

Kisseleva, T., and Brenner, D. A. (2006). Hepatic stellate cells and the reversal of fibrosis. *J. Gastroenterol. Hepatol.* 21(Suppl. 3), S84–S87. doi: 10.1111/j.1440-1746.2006.04588.x

Lee, Y. S., Kim, S. Y., Ko, E., Lee, J. H., Yi, H. S., Yoo, Y. J., et al. (2017). Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. *Sci. Rep.* 7:12698. doi: 10.1038/s41598-017-12716-6

Liu, B., Ye, B., Yang, L., Zhu, X., Huang, G., Zhu, P., et al. (2017). Long noncoding RNA IncKdm2b is required for ILC3 maintenance by initiation of Zfp292 expression. *Nat. Immunol.* 18, 499–508. doi: 10.1038/nature23712

Loewer, S., Cabili, M. N., Guttman, M., Loh, Y. H., Thomas, K., Park, I. H., et al. (2010). Large intergenic non-coding RNA-RO modules reprogramming of human induced pluripotent stem cells. *Nat. Genet.* 42, 1113–1117. doi: 10.1038/ng.7114

Lv, L. H., Wan, Y. L., Lin, Y., Zhang, W., Yang, M., Li, G. L., et al. (2012). Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. *J. Biol. Chem.* 287, 15874–15885. doi: 10.1074/jbc.M112.034588

Malizia, A. P., and Wang, D. Z. (2011). MicroRNAs in cardiomyocyte development. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 3, 183–190. doi: 10.1002/wsbm.111

Mao, K., Zhang, J., He, C., Xu, K., Liu, J., Sun, J., et al. (2014). Restoration of miR-193B sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. *Cancer Lett.* 352, 245–252. doi: 10.1016/j.canlet.2014.07.004

Matsubara, S., Lim, J. W., Tazou, B. J., Ji, H., Morizt, R. L., and Simpson, R. J. (2010). Proteomics analysis of A33 immunoaffinity-purified exosomes released from human colon tumor cell line LINM215 reveals a tissue-specific protein signature. *Mol. Cell. Proteomics* 9, 197–208. doi: 10.1074/mcp.M900152-MCP200

Matsura, K., De Giorgi, V., Schechterly, C., Wang, R. Y., Farci, P., Tanaka, Y., et al. (2016). Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C. *Hepatology* 64, 732–745. doi: 10.1002/hep.28660

Matsuura, K., De Giorgi, V., Schechterly, C., Wang, R. Y., Farci, P., Tanaka, Y., et al. (2016). Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C. *Hepatology* 64, 732–745. doi: 10.1002/hep.28660

Miyaki, H., Ichikawa, T., Kamo, Y., Taura, N., Honda, T., Shibata, H., et al. (2014). Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. *Liver Int.* 34, e302–e307. doi: 10.1111/liv.12429
Momen-Heravi, F., Saha, B., Kody, K., Catalano, D., Satishchandran, A., and Szabo, G. (2015). Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J. Transl. Med. 13:261. doi: 10.1186/s12967-015-0623-9

Mulcahy, L. A., Pink, R. C., and Carter, D. R. (2014). Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 3:10.3420/jxv1330641. doi: 10.3420/jxv.v3-234641

Nath, B., and Szabo, G. (2012). Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 55, 622–633. doi: 10.1002/hep.25497

Nieuwland, R., Berckmans, R. J., Megregian, S., Boing, A. N., Romijn, F. P., Westendorp, R. G., et al. (2000). Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 95, 930–935.

Nolte-‘t Hoen, E. N., Buermans, H. P., Waasdorp, M., Stoorvogel, W., Wauben, M. H., and ‘t Hoen, P. A. (2012). Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 40, 9272–9285. doi: 10.1093/nar/gks658

Orman, E. S., Odena, G., and Bataller, R. (2013). Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J. Gastroenterol. Hepatol. 28(Suppl. 1), 77–84. doi: 10.1111/jgh.12030

Owens, A. P. III, and Mackman, N. (2011). Microparticles in hemostasis and thrombosis. Circ. Res. 108, 1284–1297. doi: 10.1161/CIRCRESAHA.110.233056

Penfornis, P., Vallabhaneni, K. C., Whit, J., and Pochampally, R. (2016). Extracellular vesicles as carriers of microRNAs, proteins and lipids in tumor microenvironment. Int. J. Cancer 138, 14–21. doi: 10.1002/ijc.29417

Polanco, J. C., Scicluna, B. J., Hill, A. F., and Gotz, I. (2016). Extracellular vesicles isolated from the brains of TGfα510 mice seed Tau protein aggregation in a threshold-dependent manner. J. Biol. Chem. 291, 12445–12466. doi: 10.1074/jbc.M115.709485

Povero, D., Eguchi, A., Li, H., Johnson, C. D., Papouchado, B. G., Wree, A., et al. (2014). Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PloS One 9:e113651. doi: 10.1371/journal.pone.0113651

Povero, D., Eguchi, A., Niesman, I. R., Andronikou, N., De Moller Du Jue, X., Mulya, A., et al. (2013). Lipid-induced toxicity stimulates hepatocytes to release angiogenic microRNA precursors that require Vanin-1 for uptake by endothelial cells. Sci. Signal. 6ra88. doi: 10.1126/scisignal.2004512

Povero, D., Panera, N., Eguchi, A., Johnson, C. D., Papouchado, B. G., De Araujo Horcel, L., et al. (2015). Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-gamma. Cell. Mol. Gastroenterol. Hepatol. 1, 646.e4–663.e4.

Prensner, J. R., and Chinnaiyan, A. M. (2011). The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 646.e4–663.e4.

Royo, F., and Falcon-Perez, J. M. (2012). Liver extracellular vesicles in health and disease. J. Extracell. Vesicles 1:10.3420/jxv.v1330641. doi: 10.3420/jxv.v3-234641

Russos, M. W., Steuerwald, N., Norton, H. J., Anderson, W. E., Foureau, D., Chalasani, N., et al. (2017). Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 37, 757–764. doi: 10.1111/liv.13312

Salmanidis, M., Pillman, K., Goodall, G., and Bracken, C. (2014). Direct transcriptional regulation by nuclear microRNAs. Int. J. Biochem. Cell Biol. 54, 304–311. doi: 10.1016/j.biocel.2014.03.010

Scarola, M., Comiso, E., Pascolo, R., Chiariadis, R., Marion, R. M., Schneider, C., et al. (2015). Epigenetic silencing of Oct4 by a complex containing SUV39H1 and Oct4 pseudogene incRNA. Nat. Commun. 6:7631. doi: 10.1038/ncomms8631

Schuppman, D., and Kim, Y. O. (2013). Evolving therapies for liver fibrosis. J. Clin. Invest. 123, 1887–1901. doi: 10.1172/JCI66028

Shan, K., Liu, C., Liu, B. H., Chen, X., Dong, R., Liu, X., et al. (2017). Circular noncoding RNA HPAK3 mediates retinal vascular dysfunction in diabetes mellitus. Circulation 136, 1629–1642. doi: 10.1161/CIRCULATIONAHA.117.029004

Shen, J., Huang, C. K., Yu, H., Shen, B., Zhang, Y., Liang, Y., et al. (2017). The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. J. Cell. Mol. Med. 21, 986–992. doi: 10.1111/jcmm.12950

Shigehara, K., Yokomori, S., Ishibashi, O., Mizuguchi, Y., Arima, K., Kawagishi, Y., et al. (2011). Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6:e23584. doi: 10.1371/journal.pone.0023584

Shrivastava, S., Devhare, P., Sujjantarat, N., Steele, R., Kwon, Y. C., Ray, R., et al. (2015). Knockdown of autophagy inhibits infectious hepatitis C virus release by the exosomal pathway. J. Virol. 90, 1387–1396. doi: 10.1128/JVI.02383-15

Skog, J., Wurdinger, T., Van Rijn, S., Meijer, D. J., Gainehe, L., Sena-Esteves, M., et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470–1476. doi: 10.1038/nclb1800

Sohn, W., Kim, J., Kang, S. H., Yang, S. R., Cho, J. Y., Cho, H. C., et al. (2015). Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp. Mol. Med. 47:184. doi: 10.1038/emm.2015.68

Starckx, S., Batheja, A., Verheyen, G. R., Jonghe, S. D., Steemans, K., Dijkstra, B. V., et al. (2013). Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol. Pathol. 41, 795–804. doi: 10.1177/01926231246436

Sugimachi, K., Matsumura, T., Hirata, H., Uchi, R., Ueda, M., Ueo, H., et al. (2015). Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br. J. Cancer 112, 532–538. doi: 10.1038/bjc.2014.621

Szabo, G., and Momen-Heravi, F. (2017). Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Rev. Gastroenterol. Hepatol. 10, 542–552. doi: 10.1038/rgastro.2013.87

Yang et al. Extracellular Vesicles in Liver Diseases
Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., and Lotvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659. doi: 10.1038/ncb1596

Valla, D. C. (2008). Thrombosis and anticoagulation in liver disease. Hepatology 47, 1384–1393. doi: 10.1002/hep.22192

Van Rooijen, K., Pollet, J., and Calin, G. A. (2013). miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev. Mol. Diagn. 13, 183–204. doi: 10.1586/erm.12.134

Verma, V. K., Li, H., Wang, R., Hirsova, M., Liu, Y., et al. (2016). Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J. Hepatol. 64, 651–660. doi: 10.1016/j.jhep.2015.11.020

Waidmann, O., Koberle, V., Brunner, F., Zeuzem, S., Piiper, A., and Kronenberger, B. (2012). Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One 7:e45652. doi: 10.1371/journal.pone.0045652

Wang, B., Li, W., Guo, K., Xiao, Y., Wang, Y., and Fan, J. (2012). miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem. Biophys. Res. Commun. 421, 4–8. doi: 10.1016/j.bbrc.2012.03.025

Wang, F., Li, L., Piontek, K., Sakaguchi, M., and Selaru, F. M. (2018). Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 67, 940–954. doi: 10.1002/hep.29386

Wang, R., Ding, Q., Yagooob, U., De Assuncao, T. M., Verma, V. K., Hirsova, P., et al. (2015). Exosome adherence and internalization by hepatic stellate cells triggers Sphingosine 1-Phosphate-dependent migration. J. Biol. Chem. 290, 30684–30696. doi: 10.1074/jbc.M115.671735

Wang, X. Q., and Dostie, J. (2017). Reciprocal regulation of chromatin state and architecture by HOTAIRM1 contributes to temporal collinear HOXA gene activation. Nucleic Acids Res. 45, 1091–1104. doi: 10.1093/nar/gkw966

Wendler, F., Favicchio, R., Simon, T., Alifrangis, C., Stebbing, J., and Giamas, G. (2017). Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. Oncogene 36, 877–884. doi: 10.1038/onc.2016.253

Wightman, B., Ha, I., and Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855–862. doi: 10.1016/0092-8674(93)90530-4

Wong, W. Y., Lee, M. M., Chan, B. D., Kam, R. K., Zhang, G., Lu, A. P., et al. (2016). Proteomic profiling of dextran sulfate sodium induced acute ulcerative colitis mice serum exosomes and their immunomodulatory impact on macrophages. Proteomics 16, 1131–1145. doi: 10.1002/pmc.201500174

Xie, H., Ma, H., and Zhou, D. (2013). Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed. Res. Int. 2013:136106. doi: 10.1155/2013/136106

Yanez-Mo, M., Siljander, P. R., Andres, Z., Zavec, A. B., Borras, F. E., Buzas, E. L., et al. (2015). Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4:27066. doi: 10.3402/jev.v4.27066

Yang, Q., Diamond, M. P., and Al-Hendy, A. (2016). The emerging role of extracellular vesicle-derived miRNAs: implication in cancer progression and stem cell related diseases. J. Clin. Epigenet. 2:13.

Yuan, K., Wang, Q., Jia, J., and Zhao, H. (2017). A competing endogenous RNA network identifies novel miRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. Tumour Biol. 39. doi: 10.1177/1010428317707882

Zhang, C., Yang, X., Qi, G., Gao, Y., Wei, Q., and Han, S. (2018). lncRNA-HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma. Cancer Biomark. 21, 651–659. doi: 10.3233/CBM-170727

Zhang, K., Shi, Z. M., Chang, Y. N., Hu, Z. M., Qi, H. X., and Hong, W. (2014). The ways of action of long non-coding RNAs in cytoplasm and nucleus. Gene 547, 1–9. doi: 10.1016/j.gene.2014.06.043

Zhang, Z., Li, X., Sun, W., Yue, S., Yang, J., Li, J., et al. (2017). Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. Cancer Lett. 397, 33–42. doi: 10.1016/j.canlet.2017.03.004

Zomer, A., Maynard, C., Verweij, F. J., Kamermans, A., Schafer, R., Beerling, E., et al. (2015). In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 161, 1046–1057. doi: 10.1016/j.cell.2015.04.042

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Yang, Li, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.